Pharmaceuticals and capex and banking bears, oh my!

This week, a veritable profusion of pharmaceutical and health and beauty-related analysis, as brokers look at the impacts of Sigma Pharmaceutical’s suit against My Chemist/Chemist Warehouse. Also, API Pharmaceutical Ind discloses softening sales and analysts look at the introduction of another CSO entrant with CH2, plus the sale of Ansell’s sexual health and wellness division. In other news, there’s a preview of the first quarter capex figures, and what does APRA’s push to make Australian bank capital “unquestionably strong” mean for earnings?

Become a TCI Community Member Now

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

  • $1 for the first month
  • $25/month membership
  • Cancel anytime, no lock in contract
  • Access to Private Facebook group
  • Smartphone App (coming soon)